Alivus Life Sciences Ltd

- No explicit mention of any new fundraising through debt or equity in the transcript. - The company remains a net debt free company as of March 31, 2024. - There is mention of increased growth capital available with the new promoter Nirma Limited, but this refers to internal capital allocation rather than external fundraising. - Capex plans are underway, with INR129 crores spent in FY '24 and new capacities starting operations in FY '25. - Management focuses on calibrated capacity expansion based on business visibility, using existing resources. - No indications or plans disclosed for raising funds through debt or equity in the near future.

- FY '25 Capex: Around INR340 crores planned. - Major part (~INR140 crores) allocated for greenfield site development at Sholapur. - Remaining capex to complete brownfield projects at Ankleshwar and Dahej. - Regular maintenance, R&D, and quality-related capex also included. - Capacity additions planned: ~208 KL at Ankleshwar (Plant 18), ~35 KL in pharma area 4 at Dahej. - Sholapur capacity (approx. 500 KL) expected by late FY '26, with phased commissioning. - Potential additional 120 KL capacity from Plant 6 in Dahej by mid-2026. - Investments targeted at technologies to open higher-value portfolio opportunities with commercialization expected in 2-3 years. - Strategy includes calibrated capacity expansion triggered by business visibility, enabling capacity buildout within 5-6 months if needed. - Increased growth capital with new promoter Nirma to support expansion and new initiatives.

- Glenmark Life Sciences expects high single-digit growth in Glenmark Pharma (GPL) business from FY '24 base. - Overall FY '25 top-line growth is projected at low to mid-teens, supported by a robust external business and expected recovery in the Japanese market. - Volume growth is anticipated around 10% to 11% with a price erosion of approximately 4% to 4.5%. - The CDMO segment is expected to see revenue growth, with plans to increase the portfolio, aiming for about INR 500-600 crores in 4 years and potentially INR 1,000 crores longer term. - Capacity expansions at Ankleshwar and Dahej operational beginning Q1 FY '25 will support growth. - The high-potency API pipeline (with 17 APIs and a $37 billion addressable market) will contribute significantly starting about 2 years from now. - Despite some Q4 delays due to geopolitical issues and policy alignment, order books remain strong, supporting growth outlook.

- Glenmark Life Sciences expects overall revenue growth in FY '25 to be low to mid-teens percentage, driven by a high single-digit growth in Glenmark business (Generic API) and robust external business including CDMO and Japan market recovery. - EBITDA margins are projected in the range of 28% to 30%, considering a 100-150 basis points reduction due to discontinuation of PLI benefits. - The company anticipates volume growth of around 10-11%, with a price erosion of 4-4.5%. - One-time employee bonus costs, which impacted FY '24 margins, are expected to normalize from Q1 FY '25 onward. - Capacity expansions in Ankleshwar and Dahej starting FY '25 Q1 and subsequent phased additions are expected to support future growth. - The company foresees stable profitability with adjusted EBITDA margins around 31.8% after one-time adjustments in FY '24.

- Glenmark Life Sciences reports a strong order book for the coming quarters despite recent supply chain disruptions. - Demand across most markets remains stable, with the exception of Japan, where inventory destocking is ongoing but expected to recover in H2 FY'25. - The company anticipates robust growth in both Generic API and CDMO businesses supported by new capacity additions. - There is no explicit quantification of the exact pending order value disclosed in the call. - Business visibility typically spans 1 to 2 quarters, allowing capacity to be scaled within approximately 5-6 months when new business arises. - The company is actively managing supply chain challenges caused by the Red Sea crisis to fulfill orders timely. - Overall, the outlook remains positive with strong order inflows and growth capital available for expansion.